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Noninfectious Pr55gag virus-like particles containing high quantities of oligomeric human immunodeficiency virus type 1
(HIV-1) envelope (Env) proteins represent potential candidate immunogens for a vaccine against HIV-1 infection. Thus,
chimeric env genes were constructed encoding the HIV-1 exterior glycoprotein gp120 which was covalently linked at different
C-terminal positions to a transmembrane domain (TM) from the Epstein–Barr virus (EBV) major Env glycoprotein gp220/
350. All chimeric Env-TM polypeptides as well as the wild-type HIV Env proteins were equally produced and incorporated
at the outer surface of insect cells using the baculovirus expression system. In the presence of coexpressed HIV Pr55gag
polyproteins significantly decreased amounts of wild-type Env proteins were presented at the cell surface, whereas the
membrane incorporation of the Env-TM chimeras was not affected. Biochemical and immunoelectron microscopical analysis
of particles that were efficiently released from these cells displayed the incorporation of both wild-type Env and chimeric
Env-TM proteins on the surface of VLPs. However, the quantities of particle-associated chimeric Env-TM proteins exceeded
those of incorporated wild-type Env proteins by a factor of 5–10. Chemical cross-linking and subsequent polyacrylamide
gel electrophoresis of VLP-entrapped Env proteins revealed that the chimeric Env-TM proteins form homodimers and a
higher-order oligomer, similar to that observed for wild-type Env proteins. Thus, the results of this study clearly demonstrate
that the replacement of the gp41 transmembrane protein of gp160 by a heterologous, EBV gp220/350-derived membrane
anchor provides an effective strategy to incorporate high quantities of oligomeric HIV gp120 proteins on the surface of
Pr55gag virus-like particles. q 1997 Academic Press
INTRODUCTION to include all information required for the formation of
particulate structures (Delchambre et al., 1989; Wills
Various polyvalent particulate structures have been
and Craven, 1991). The incorporation of foreign antigens
previously demonstrated to possess intrinsic adjuvant
into retroviral particles has been originally described
properties (Jenkins et al., 1991; Layton et al., 1993;
using the Gag proteins of Rous sarcoma virus (RSV) and
Schirmbeck et al., 1994). Consequently, particle-based
Moloney murine leukemia virus (MLV) as a particulate
antigen delivery systems have been established by re-
carrier (Jones et al., 1990; Weldon, Jr. et al., 1990). For
combinant DNA technology to stimulate the immune re-
HIV, expression of Pr55gag by recombinant vaccinia vi-
sponse to selected immunodominant epitopes of vari-
ruses and baculoviruses results in the formation of non-
ous viruses for vaccine purposes. For example, chimeric
infectious virus-like particles (VLPs) that lack HI-viral
hepatitis B virus (HBV) core and surface antigen (von
RNA (Gheysen et al., 1989; Vernon et al., 1991; Royer et
Brunn et al., 1991; Schlienger et al., 1992; Michel et al.,
al., 1991). The identification of distinct domains within
1993; Schirmbeck et al., 1994) as well as recombinant
the HIV-1 Pr55gag precursor, which are dispensable for
papilloma virus L1/L2 (Lin et al., 1993; Breitburd et al.,
the formation and release of VLPs from eukaryotic cells
1995; Kirnbauer et al., 1996) and yeast retrotransposon
(Wagner et al., 1991), led to a variety of Gag mutants
Ty-p1 virus-like particles (Griffiths et al., 1991; Harris et
allowing the incorporation of different epitopes derived
al., 1992) have been recently shown to elicit both B-cell
from other HIV reading frames such as env or nef into
and T-cell responses to the particulate carrier moiety
chimeric VLPs (Wagner et al., 1994). When administered
and the inserted foreign determinants. Also retroviral
to BALB/c mice, these particles readily induced cytolytic
Gag precursor proteins have been previously shown
T-cells specifically recognizing Env-derived sequences
that were inserted into different positions of the gag
1 Present address: DAKO Diagnostika GMBH, Am Stadtrand 52, reading frame (Griffiths et al., 1993; Wagner et al., 1995;
22047 Hamburg.
Wagner et al., 1996). However, although such particles2 To whom correspondence and reprint requests should be ad-
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ngate.uni-regensburg.de. polyprotein, antibody titers to the presented foreign epi-
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topes were comparably low and showed only a weak when compared to wild-type Env proteins. Moreover, re-
sults obtained with chemical cross-linking analysis sug-or no neutralizing activity (Luo et al., 1992; Griffiths et
al., 1993; Wagner et al., 1996). gest an oligomeric structure of particle-entrapped gp120
derivatives. Therefore the presented system is wellAlternatively, the incorporation of oligomeric HIV Env
proteins into Pr55gag VLPs may be a promising strategy suited for studying the protein incorporation into retrovi-
ral VLPs. In addition, these noninfectious envelopedin the design of a rational HIV candidate vaccine. The
exterior Env protein gp120 represents the major target Pr55gag VLPs provide an attractive approach for the devel-
opment of a candidate vaccine against HIV infection.for neutralizing antibodies, which may play an important
role in inducing protection from infection or disease pro-
gression (Steimer et al., 1991; Haigwood et al., 1992; MATERIALS AND METHODS
Sattentau and Moore, 1995). The assembly of recombi-
Media, cells, and viruses
nant pseudovirions that contain the Pr55gag structural
protein as well as full-length HIV Env glycoproteins was Spodoptera frugiperda Sf9 cells were maintained in
TC100 medium supplemented with 10% FCS (Gibco-BRL,previously reported using the vaccinia virus expression
system (Haffar et al., 1990; Vzorov et al., 1991) or stable Grand Island, NE). Wild-type Autographa californica nu-
clear polyhedrosis viruses (AcNPVs) and recombinanttransfected mammalian cells (Rovinski et al., 1992; Kraus-
slich et al., 1993; Rovinski et al., 1995). Alternatively, the baculoviruses were propagated on Sf9 insect cells as
described previously (Smith et al., 1985). Titers of bacu-baculovirus expression system provides by far the most
efficient system for the overexpression of the Pr55gag lovirus stocks were determined by plaque assay (O’Reily
et al., 1992). For large scale preparation of recombinantpolyprotein and its assembly into VLPs (Wagner et al.,
1992). However, the expression patterns of the HIV Env antigens from serum-free cell culture supernatants
(SF900; Gibco), HighFive cells derived from Trichoplusiaglycoproteins in the baculovirus system showed some
unusual features in that the gp160 precursor seemed to ni egg cell homogenates (Invitrogen Inc., San Diego, CA)
were used for the infection with the recombinant baculo-be inefficiently cleaved and mainly remained cell associ-
ated (Rusche et al., 1987; Hu et al., 1987; Wells and viruses.
Compans, 1990).
HIV-SequenceFor HIV and SIV, determinants within the cytoplasmic
domain of the transmembrane protein and the viral matrix All amino acid positions given in the text refer to the
protein have been implicated in modulating the cell sur- HIV-1LAI sequence.
face expression of the Env proteins (Owens et al., 1991)
and directing their subsequent incorporation into virions Monoclonal antibodies
(Yu et al., 1992; Gonzalez et al., 1993; Dorfman et al.,
A HIV gp120-specific murine monoclonal antibody1994; Bugelski et al., 1995; Freed et al., 1995; Freed and
(mab NEA 9305) recognizing a central motive of the V3-Martin, 1995). Alterations in the cytoplasmic domain of
loop region (RIQRGPGRAFVTIGKI) and a gp41-specificthe SIV and HIV-2 transmembrane protein significantly
murine monoclonal antibody (mab NEA 9303) were pur-increased the level of Env proteins on the surface of
chased from DuPont Canada, Inc. (Markham, Ontario).viruses (Mulligan et al., 1992; Zingler and Littman, 1993;
The gp120-specific murine mab 133/237 recognizingLaBranche et al., 1995), whereas various deletions in the
amino acids 64 to 73 and mab 133/192 recognizing aC-terminal region of the cytoplasmic region of HIV-1 gp41
discontinuous epitope within gp120 (Niedrig et al., 1992)were demonstrated to diminish the incorporation of Env
as well as a human CD4-IgG construct (CD4-2D-H23;proteins into HIV virions (Dubay et al., 1992; Yu et al.,
Langner et al., 1993) were generously provided by Dr.1993). However, determinants that positively or nega-
Matthias Niedrig (Robert Koch Institute, Berlin). A Pr55gag-tively affect the incorporation of Env proteins into Pr55gag
specific monoclonal antibody (mab 16/4/2) has been pre-VLPs appear to depend largely on the cell culture system
viously mapped to amino acids 307–336 within theand have not been identified so far.
p24(CA) moiety of the Pr55gag polyprotein (Wolf et al.,Previous reports by others and us indicated that her-
1990). Mab 64/D7 reacts with the external portion of thepesvirus-derived glycoproteins were efficiently incorpo-
EBV major glycoprotein gp220/350 (unpublished obser-rated at the outer surface of Pr55gag virus-like particles
vation).by using the baculovirus expression system (Osterrieder
et al., 1995; Garnier et al., 1995). Based on this observa-
Construction of plasmids
tion, we investigated the possibility of increasing the
packaging of HIV Env proteins on the outer surface of A baculovirus transfer vector encoding the HIV-1 gag
gene (pVLPr55) has been constructed as described pre-Pr55gag VLPs by replacing gp41 of the gp160 precursor
protein with a heterologous membrane anchor derived viously (Wagner et al., 1992). Subcloning of the coding
sequence of the HIV-1 gp160 Env protein and chimericfrom the EBV major glycoprotein gp220/350. Our results
clearly indicate a significantly enhanced incorporation of env genes including parts of the external glycoprotein
gp120 was achieved in a pUC18 derivative named pUC-Env-TM chimeras on the outer surface of Pr55gag VLPs
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EH. pUC-EH was created by replacing the original poly- 5TM, and pVLgp120-20TM) encode the full-length gp160
as well as the HIV-1 exterior Env glycoprotein gp120linker of pUC18 by a 5*-EcoRI–BclI–MroI–XbaI– PstI–
HindIII-3* multiple cloning site. For this purpose, two fused at different C-terminal positions in gp120 to a type
I transmembrane region from the EBV Env protein gp220/synthetic oligonucleotides a (5*-AAT TCT GAT CAT CCG
GAT CTA GAC TGC AGA-3*) and b (5*-AGC TTC TGC 350 (Fig. 1). All subcloned DNA-sequences including the
flanking regions were verified by double-strand DNA se-AGT CTA GAT CCG GAT GAT CAG-3*) were annealed
and inserted into the EcoRI–HindIII-linearized vector quencing.
fragment of pUC18. DNA-fragments encoding the com-
Generation of recombinant baculovirusesplete gp160, the full-length gp120, or carboxy (C)-termi-
nally by 5 or 20 amino acids truncated variants of gp120 The Autographa californica nuclear polyhedrosis virus
were obtained from plasmid pBH102 by polymerase (AcNPV) recombinants used in this study were AcPr55
chain reaction (PCR). Primers c (5*-ATA TTA GAA TTC (Wagner et al., 1992), Acgp160, Acgp120-TM, Acgp120-
ATG AGA GTG AAG GAG AAA TAT CAG C-3*), including 5TM, and Acgp120-20TM. Recombinant baculoviruses
a 5*-EcoRI restriction site (italics) as well as the ATG were established in Sf9 insect cells by cotransfection of
start codon (bold-faced), and d (5*-ATA TTA CTG CAG infectious Autographa californica nuclear polyhedrosis
TTA TAG CAA AAT CCT TTC C-3*), containing a 5*-PstI viral DNA and pVL baculovirus transfer vector DNA con-
site (italics), were used to amplify the gp160 open read- taining the foreign gene (Smith et al., 1985). Polyhedrin-
ing frame. The amplified DNA product was digested with negative plaques were isolated following several rounds
EcoRI/PstI and inserted into the EcoRI/PstI vector frag- of plaque purification, and high-titer stocks of recombi-
ment of pUC-EH, resulting in pUCgp160. PCR products nant baculoviruses were prepared as described pre-
encoding gp120 and the C-terminally truncated gp120 viously (Wagner et al., 1992).
derivatives were obtained by using the 5*-primer c to-
gether with the 3*-primer e (5*-ATA TTA TCC GGA CAC Detection and quantification of chimeric proteins
CAC TCT TCT CTT TTA TCC), primers c and f (5*-ATA
Recombinant proteins were expressed in Sf9 or High-TTA TCC GGA GGA CTT TGC CTT GGT GGG TGC TAC
Five insect cells after (co)infection with AcNPV recombi-TCC-3*), and primers c and g (5*-ATA TTA TCC GGA TTT
nants at a multiplicity of infection (m.o.i.) of 10 for eachATA TTT ATA TAA TTC ACT TCT CC-3*). The primers e,
virus. Synthesis of the recombinant proteins was demon-f, and g include a MroI restriction site indicated in italics,
strated at Day 3 p.i. by separating the cell lysates onrespectively. The amplified DNA fragments were di-
sodium dodecyl sulfate (SDS)–10% polyacrylamide gelsgested with EcoRI/MroI and inserted into the EcoRI/MroI
followed by conventional Western blot analysis (Sam-sites of pUC-EH vector. The resulting plasmids were de-
brook et al., 1989). Recombinant proteins were specifi-signed as pUCgp120, pUCgp120-5, and pUCgp120-20. In
cally visualized using the indicated monoclonal antibod-order to allow stable anchoring of gp120 and its deriva-
ies. The concentration of Pr55gag proteins was deter-tives on cellular membranes, the transmembrane region
mined using a commercial p24 capture assay (Abbottof the Epstein–Barr virus (EBV) glycoprotein gp220/350
Diagnostics, Wiesbaden, Germany). The quantities ofwas linked to the C-terminus of the gp120 variants. For
particle entrapped Env proteins were calculated by com-this purpose, a gene fragment encoding the 22 amino
parative Western immunoblotting of normalized particleacid spanning transmembrane domain (TD) and the short
preparations and serial twofold dilutions (0.2– 3.2 mg) ofcytoplasmic region (CR) (27 amino acids) of the gp220/
highly purified rgp120 protein (Genentec Inc., San Fran-350 gene was amplified by PCR from the plasmid
cisco, CA). Additionally, a commercial gp120 capturepBRBamHI-L (Skare and Strominger, 1980) using primers
ELISA kit (Intracel Corp., Cambridge, MA) was used toh (5*-ATA TTA TCC GGA AGC GGG GCA GGA TCC ATG
verify the quantities of particle-associated Env proteins.CTA GTA CTT CAA TGG GCC TCT CTG-3*) containing a
spacer that encodes a flexible stretch of 6 amino acids
APAAP immunostaining and FACScan analysis
(-S-G-S-G-A-G-; bold-faced) as well as a MroI site (italics)
and primer i (5*-ATA TTA CTG CAG TTA TAC ATA CCT Cell surface expression of the chimeric Env proteins
was shown at Day 3 after (co)infection of Sf9 cells withCTC GGC CTC-3*), containing a stop codon (bold-faced)
and a PstI restriction site (italics). After digestion with the recombinant AcNPVs. After extensive washing in PBS
(10 mM phosphate buffer, pH 8.0, containing 0.15 MMroI/PstI, the amplified PCR fragment was inserted into
the chimeric gp120 constructs between the MroI and NaCl), cells were fixed with 2% glutaraldehyde for 10 min.
Following three more washes in PBS, the fixed cells werePstI sites of the plasmids pUCgp120, pUCgp120-5, and
pUCgp120-20. The resulting vectors were termed incubated with different dilutions of the indicated Env-
specific monoclonal antibodies or a human CD4-IgG con-pUCgp120-TM, pUCgp120-5TM, and pUCgp120-20TM,
respectively. To establish recombinant baculoviruses the struct for 1.5 hr at 377. Unbound antibodies were removed
by three washing steps using PBS. Antibodies, whichpUC-derived Env constructs were subcloned into the
EcoRI/PstI-digested pVL1393 baculo transfer vector. The specifically bound to gp120 exposed on the cell surface,
were detected by an alkaline phosphatase anti-alkalineresulting plasmids (pVLgp160, pVLgp120-TM, pVLgp120-
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phosphatase (APAAP) staining procedure as described SDS–10% polyacrylamide gels, and analyzed by immu-
noblotting using monoclonal antibodies directed eitherin the manufacturers protocol (Dako Diagnostika, Ham-
burg, Germany). Surface expression of Env glycoproteins to the V3 domain within gp120 (mab NEA 9305) or the
p24(CA) moiety within Pr55gag (mab 16/4/2).on infected cells was further determined by flow cytome-
try using a FACScan analyzer (Becton–Dickinson, San
Electron microscopyJose, CA). For this purpose, 2 1 105 Sf9 cells were har-
vested at Day 2 after (co)infection with the indicated
Sf9 cells (108) were harvested 3 days after (co)infection
AcNPV recombinants and resuspended in 100 ml of a
with the indicated AcNPV recombinants (m.o.i.  10 for
1:500 dilution of the anti-gp120 mouse monoclonal anti-
each virus). Specimens for ultrathin sectioning were pre-
bodies 133/237 or 133/192 dissolved in PBS supple-
pared as described previously (Wagner et al., 1994). Sec-
mented with 10% FCS and 10 mM NaN3. After 30 min
tions of 25- to 75-nm thickness were cut with a diamond
incubation at 377, cells were washed in PBS and incu-
knife and mounted on uncoated copper grids. The sec-
bated for another 30 min in a solution of 100 ml fluores-
tions were poststained with 100 mmol lead (II) citrate,
cein isothiocyanate (FITC)-conjugated rabbit-anti-mouse
pH 12.6. All pictures were taken with Siemens Elmiskop
F(ab*)2-fragment (20 mg/ml; Dako). After three more
101 electron microscope. The magnification was cali-
washes in PBS, cells were fixed for 1 hr in 70% methanol,
brated with a cross line grating replica. Immunoelectron
sedimented (500 g), and resuspended in PBS. The cellu-
microscopy of VLPs was performed essentially as de-
lar RNA was degraded by incubation with RNase A (1
scribed by Osterrieder et al. (1995). Purified VLPs were
mg/ml; Boehringer Mannheim, Mannheim, Germany) for
adsorbed to grids after fixation with 2% glutaraldehyde.
30 min at 377. Propidium iodide was added to a final
Grids were washed in TBS, blocked with 3% gelatin in
concentration of 1 mg/ml to determine the DNA content.
TBS for 1 hr at RT, and incubated with the V3-specific
Cells were analyzed with a FACScan flow cytometer
mab NEA 9305 in TBS for 1 hr at RT. After three washes
(Becton–Dickinson) using Cell-fit software (Becton–
in TBS, grids were floated on an anti-mouse IgG immuno-
Dickinson) in a dual parameter fluorescence analysis of
gold conjugate (particle size: 5 nm; Sigma, Deisenhofen,
antibody and DNA. A pulse processor used on the red
Germany) for 1 hr at RT. After three washes in TBS grids
fluorescence signal allowed to exclude cell debris as
were contrasted with phosphoric tungstic acid and exam-
well as dead and aggregated cells from the analysis.
ined in an electron microscope (Zeiss EM 10C/CR).
Purification and biochemical characterization of VLPs Chemical cross-linking
Supernatants of HighFive cells coinfected with Pr55gagSerum-free supernatants of HighFive cells expressing
Pr55gag in addition to either gp160 or one of the Env-TM and Env-TM recombinant baculoviruses were clarified
by centrifugation at 2,000 g for 10 min at 47 and thenproteins were collected 3–5 days p.i. and clarified by
centrifugation at 2,000 g for 10 min at 47. Concentration centrifuged through a 30% sucrose cushion at 100,000 g
for 2.5 hr at 47. Pelleted VLP preparations were allowedof virus-like particles (VLPs) from precleared culture su-
pernatant was achieved by Centrisat I tubes (Satorius to suspend overnight in PBS, pH 8.0, at 47. Aliquots (2
ml) of the concentrated material were layered onto a 10-AG, Go¨ttingen, Germany) or sedimentation through a 30%
sucrose cushion at 100,000 g for 2.5 hr at 47. Pelleted ml 10–60% sucrose gradient made in PBS and centri-
fuged at 100,000 g for 16 hr at 47. Antigens sedimentingVLP preparations were allowed to suspend overnight in
PBS, pH 8.0. Aliquots (2 ml) of the concentrated material at a sucrose density of 1.15–1.19 g/cm3 were collected,
diluted in 3 vol of PBS, repelleted at 100,000 g for 2.5 hrwere layered onto a 10-ml 10–60% sucrose gradient in
PBS and centrifuged at 100,000 g for 16 hr at 47. Fractions at 47, and resuspended in PBS to a final concentration of
1–5 mg protein per milliliter. Highly purified recombinantof 0.6 ml were collected and divided each into two ali-
quots. Aliquot 1 was diluted with PBS to a total volume gp160 produced in Chinese hamster ovary cells by Im-
muno (Vienna, Austria) was suspended in PBS andof 1 ml and VLPs were pelleted at 16,000 rpm for 40 min
at 47 in an Eppendorf centrifuge. Antigen preparations served as a control antigen. Probes were treated with 0.3
or 1.5 mM bis(sulfosuccinimidyl)suberate (BS3) (Piercewere resuspended in sample buffer (Laemmli, 1970) and
separated by electrophoresis on a SDS–10% polyacryl- Chemical Co., Rockford, IL), incubated at 377 for 30 min,
and quenched for 15 min with 50 mM Tris, pH 7.5. Nonamide gel followed by Western immunoblot as described
previously (Wagner et al., 1994). BS3-treated antigens served as controls. The probes
were solubilized by the addition of a solution containingImmunoprecipitation of VLPs from p24(CA) peak frac-
tions (fractions 12–14) obtained after sucrose sedimen- 4% SDS, 100 mM Tris, pH 6.8, 10% glycerin, 10% 2-mer-
captoethanol, 0.01% bromphenol blue and boiling for 10tation analysis was performed with 2 to 10 ml of a CD4-
IgG chimeric antibody according to a protocol described min. Each sample was then subjected to electrophoresis
on SDS–5% polyacrylamide gels under reducing bufferby Sambrook et al. (1989), except that no detergent was
used in the buffers. Immunoprecipitates were diluted in conditions. Proteins were transferred to nitrocellulose,
immunoblotted with antibodies directed against gp120sample reducing buffer, separated by electrophoresis on
AID VY 8669 / 6a3e$$$561 07-30-97 14:49:39 viral AP: VY
14 DEML ET AL.
FIG. 1. Schematic representation of chimeric Env-TM glycoprotein mutants. The wild-type HIV-1 glycoprotein precursor gp160 is diagrammed at
the top of the figure. The gp41 transmembrane domain of gp160 was replaced by a heterologous Epstein–Barr virus (EBV)-derived type I transmem-
brane region (TM), consisting of a 22 amino acid spanning transmembrane domain (TD) and a short cytoplasmic region (CR) (27 amino acids),
which was covalently linked to the C-terminus of gp120 by a flexible-S-G-S-G-A-G-hinge region (gp120-TM). Additionally derivatives of the gp120-
TM construct were generated lacking 5 (gp120-5TM) or 20 C-terminal amino acids (gp120-20TM) of the gp120 moiety. The gp120-TM protein as
well as the gp120-5TM and gp120-20TM polypeptides were designated as Env-TM. Abbreviations of recombinant baculoviruses expressing the
different chimeric genes are given on the right, the number of amino acids encoded by the chimeric genes are indicated on the left side of the
figure. A diagram of the particle forming Pr55gag polyprotein is shown below.
and p24(CA), and then probed by using a peroxidase- recombinant baculoviruses at a m.o.i. of 10. Cells were
harvested 3 days postinfection (p.i.) and analyzed byconjugated secondary antibody (Dako). Immunoblots
were visualized by enhanced chemoluminescence (ECL) immunoblotting. Env proteins were visualized by using
the gp120/V3-specific monoclonal antibody NEA 9305.(Amersham, Little Chalfont, England).
Predominant protein bands with apparent molecular
weights consistent with those of the wild-type HIV EnvRESULTS
proteins gp160 and gp120 as well as the chimeric Env-
Expression of chimeric Env-TM glycoproteins in TM polyproteins (137 kDa for gp120-TM, 135 kDa for
insect cells gp120-5TM, and 132 kDa for gp120-20TM) were visual-
ized in lysates of insect cells infected with the corre-
A set of recombinant baculoviruses was constructed sponding Env recombinant AcNPVs (Fig. 2A). The de-
to study the incorporation of genetically engineered Env-
TM glycoproteins into HIV Pr55gag virus-like particles
(VLPs). The chimeric Env glycoprotein gp120-TM was
established by replacing the gp41 transmembrane pro-
tein of the HIV gp160 Env-precursor with a heterologous
type I transmembrane region (TM) of the Epstein– Barr
virus (EBV) major glycoprotein gp220/350 (Fig. 1). A flexi-
ble hinge region consisting of six amino acids (-S-G-S-
G-A-G-) was introduced between gp120 and the heterolo-
gous membrane anchor to support correct and indepen-
dent folding of both domains. Derivatives of gp120-TM
FIG. 2. Analysis of Sf9 cell lysates 3 days after infection with different
have 5 (gp120-5TM) or 20 amino acids (gp120-20TM) recombinant AcNPVs at a multiplicity of infection (m.o.i.) of 10 per cell.
deleted from the C-terminus of the gp120 moiety to avoid Sf9 cells were infected with Acgp120-TM (lanes 4), Acgp120-5TM (lanes
5), Acgp120-20TM (lanes 6), and Acgp160 (lanes 7). Noninfected Sf9unspecific processing at cryptic cleavage sites located
insect cells (lanes 1) or cells infected by AcWt (lanes 2) or AcPr55within the C-terminus of the exterior HIV Env-protein
(lanes 3) were used as negative controls. Polypeptides were separated(Morikawa et al., 1990, 1993).
by 10% SDS–PAGE and analyzed by immunoblotting with (A) a gp120/
To investigate and compare the synthesis of both HIV V3-specific monoclonal antibody and (B) an anti-gp41 monoclonal anti-
wild-type Env polypeptides and chimeric Env-TM pro- body. Arrows at the right indicate the position of the HIV wild-type Env
proteins. Sizes are indicated in kilodaltons.teins, Sf9 insect cells were infected with various Env
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tected quantities of chimeric Env-TM polypeptides were and cells that were infected with wild-type baculovi-
ruses or with AcNPVs expressing the Pr55gag polyproteincomparable to that of the wild-type HIV Env-polypep-
tides. Proteins migrating at a lower molecular weight were not recognized by the Env-specific antibodies.
These data suggest that the targeting of the externalare due to unspecific degradation of the recombinant
proteins by cellular proteases. Identical results were ob- glycoprotein gp120 to the surface of Sf9 insect cells
was not affected by the substitution of the autologoustained when the Env-specific mab 133/237 binding
amino acids 64 –73 and mab 133/192, recognizing a dis- transmembrane protein gp41 with the heterologous,
EBV gp220/350-derived transmembrane domain.continuous epitope within gp120, were used for immuno-
logical detection of the Env glycoproteins (data not
shown). Thus, C-terminal truncations of gp120 by either Influence of coexpressed Pr55gag on the synthesis
5 or 20 amino acids and fusion of the gp120 derivatives and surface expression of chimeric Env-TM
to a heterologous EBV-derived membrane anchor nei- polypeptides
ther resulted in a reduced expression nor in a decreased
stability of these polypeptides when compared to wild- To determine whether the incorporation of either wild-
type Env proteins or the Env-TM chimeras into the celltype HIV Env proteins. Lysates of uninfected insect cells
or cells which were infected by wild-type AcNPVs (AcWt) membrane is affected by the coexpression the particle
forming Pr55gag precursor, Sf9 cells were simultaneouslyor Pr55gag recombinant baculoviruses (AcPr55) (Wagner
et al., 1992) were negative for Env-TM or wild-type HIV infected with AcNPVs expressing the Pr55gag polyprotein
and one of the Env protein recombinant AcNPV. For con-Env proteins. A monoclonal antibody recognizing the
transmembrane protein gp41 specifically detected both, trol, cells remained uninfected or were coinfected with
AcWt and AcPr55. Simultaneous expression of Pr55gagthe gp160 precursor and a 41-kDa cleavage product in
lysates of insect cells infected with Acgp160 (Fig. 2B). and gp160 or one of the chimeric Env-TM polypeptides
in coinfected insect cells was confirmed by immunofluo-However, cleavage of gp160 into gp120 and gp41 func-
tional subunits does not seem to be efficient in insect rescence using monoclonal antibodies to the p24(CA)
moiety of the Pr55gag precursor (mab 16/4/2) and gp120cells, confirming previous observations by others (Hu et
al., 1987; Rusche et al., 1987; Wells and Compans, 1990). (mab NEA 9305) (data not shown). When analyzed by
immunoblotting, lysates of Sf9 cells harvested 3 daysNo anti-gp41 reactive bands were detected in lysates of
uninfected cells and cells infected with baculoviruses after coinfection with the indicated AcNPV recombinants
exhibited no differences in the overall amount of theexpressing Pr55gag or Env-TM chimeras.
Pr55gag precursor (Fig. 4A). More importantly, similar
amounts of Env glycoproteins were visualized in allCell surface expression of chimeric Env-TM
tested cell lysates by Western immunoblotting irrespec-polypeptides
tive of whether gp160 or one of the chimeric Env-TM
proteins was coexpressed with Pr55gag (Fig. 4B). As as-The cell surface expression of wild-type HIV Env pro-
teins and the Env-TM chimeras was assessed by sessed by a commercial p24 sandwich assay, coexpres-
sion of Pr55gag with one of the Env polypeptides led to aAPAAP immunostaining and flow cytometric analysis.
For that purpose Sf9 insect cells were either nontreated, 40–60% reduction in the Pr55gag synthesis when com-
pared to cells infected with AcPr55, only. Similarly, theinfected with wild-type baculoviruses or with AcNPVs
expressing gp160 or the gp120-TM chimeras, and then overall quantities of synthesized Env-TM chimeras and
wild-type HIV Env proteins were reduced by a factor ofharvested early at Day 2 p.i. to avoid virus-mediated
cytopathic effects. APAAP immunostaining was per- 1.5 to 2. This indicates that the capacity of the coinfected
cells to produce recombinant proteins from the polyhe-formed with the gp120-specific monoclonal antibodies
(mabs) 133/192, 133/237, NEA 9305, as well as a chime- drin promoter is limited and almost equally distributed
to each of the expression units. However, analyzing theric human CD4-IgG construct. In all cases, a clear
gp160- and gp120-specific staining of the cell mem- influence of coexpressed Pr55gag on the cell surface pre-
sentation of the Env proteins, flow cytometric analysisbrane was noticed (data not shown). To compare the
cell surface expression of wild-type Env and the chime- demonstrated the amounts of presented wild-type Env to
be significantly reduced by a factor of two to three whenric Env-TM glycoproteins under more quantitative as-
pects, FACScan analysis was performed with infected compared to the presented modified Env-TM proteins
(Fig. 5). This observation indicates that the incorporationSf9 cells by using the gp120-specific mab 133/237. All
variants of the chimeric gp120-TM glycoprotein as well of wild-type Env proteins into the membrane of baculovi-
rus-infected insect cells may be limited by a specificas wild-type Env polypeptides were detected at the cell
surface to a comparable extent (Fig. 3). Similar results interaction of the transmembrane protein gp41 and do-
mains within the Pr55gag polyprotein. In contrary, apartwere obtained by using mab 133/192 (binding to a dis-
continuous epitope within gp120) for immunological de- from the fact that coexpression of Pr55gag and Env pro-
teins reduces the amounts of cell-associated Env-TM bytection of the various cell surface-exposed Env glyco-
proteins (data not shown). In contrast uninfected cells a factor of 1.5 to 2, the incorporation of the chimeric
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FIG. 3. One-dimensional histograms representing flow cytometric measurements of different Env proteins expressed on the surface of Sf9 insect
cells. Fluorescence intensities are indicated in log scale. Sf9 cells infected with baculoviruses expressing (C) Pr55gag (D, E) gp160, or (F–H) the indicated
hybrid Env-TM proteins at a m.o.i. of 5 per cell for 48 hr were stained for FACScan analysis with (A–C, E–H) a gp120-specific monoclonal antibody
(mab 133/237) and then labeled with FITC-conjugated anti-mouse IgG antibody. (A) Noninfected Sf9 insect cells or (B) cells infected with AcWt were
used as negative controls. (D) The background of fluorescence was determined by treating Acgp160-infected Sf9 cells with an irrelevant monoclonal
antibody against the EBV-glycoprotein gp220/350 (mab 64D7) and consecutive incubation of the cells with a FITC-conjugated anti-mouse IgG antibody.
(I) Comparative overlapping of histograms of noninfected Sf9 insect cells (black histogram) and cells infected with Acgp120-TM (red histogram) or
Acgp160 (blue histogram). The data represent the mean of three experiments, with standard deviations being equivalent to 5 to 10% of the mean.
glycoproteins into the cell membrane seemed not to be infected with AcPr55 alone or coinfected with recombi-
affected by the simultaneous synthesis of the Pr55gag nant baculoviruses expressing the Pr55gag polyprotein
polyprotein (Fig. 6). (AcPr55) and AcWt or one of the AcNPV recombinants
Acgp160, Acgp120-TM, Acgp120-5TM, or Acgp120-20TM,
Incorporation of chimeric Env-TM glycoproteins into respectively. Seventy-two hours postinfection cell culture
budding virus-like particles supernatants and infected cells were separated and ana-
lyzed either by sucrose sedimentation analysis or ultra-In order to assess the incorporation of wild-type Env
thin sectioning electron microscopy. Morphological anal-proteins and chimeric Env-TM polypeptides into budding
virus-like particles, HighFive insect cells were either ysis of coinfected cells revealed efficient budding of re-
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FIG. 5. One-dimensional histograms representing flow cytometric measurements of Env proteins expressed on the outer surface Sf9 insect cells.
Fluorescence intensities are indicated in log scale. Sf9 cells coinfected with baculoviruses expressing the Pr55gag polyprotein and (B) gp160 or (C–
E) the indicated chimeric Env-TM proteins (m.o.i.  5 for AcPr55 and m.o.i.  10 for each Env-recombinant AcNPV) for 48 hr were stained for flow
cytometric analysis with (A– F) the gp120-specific monoclonal antibody 133/237 and then labeled with FITC-conjugated anti-mouse IgG antibody
(DAKO). (A) Sf9 insect cells coinfected with AcWt and AcPr55 were used as negative controls. Cell populations analyzed were 95% infected with
AcPr55, as determined by Pr55gag expression on permeabilized cells by using fluorescence microscopy. (F) Comparative overlapping of histograms
of Sf9 insect cells coinfected with AcPr55 and AcWt (black histogram), Acgp120-TM (red histogram), or Acgp160 (blue histogram). The data represent
the mean of three experiments, with standard deviations being equivalent to 5 to 10% of the mean.
FIG. 6. Influence of the Pr55gag polyprotein on the surface expression of gp160 and chimeric Env-TM polypeptides on Sf9 insect cells. Comparative
overlapping of histograms of Sf9 insect cells infected with (A) AcWt, (B) Acgp160, and (C) Acgp120-TM (black histograms), or coinfected with AcPr55 and
(A) AcWt, (B) Acgp160, and (C) Acgp120-TM (red histograms). Cells were stained with the gp120-specific mab 133/237 and labeled with FITC-conjugated
anti-mouse IgG antibody. The data represent the mean of three experiments, with standard deviations being equivalent to 5 to 10% of the mean.
combinant VLPs, which resembled immature HIV-virions sity of 1.13–1.19 g/cm3, with a peak at 1.16 g/cm3 for all
coinfections tested (Fig. 7A), which is consistent with theand Pr55gag VLPs (Gheysen et al., 1989; Wagner et al.,
1994). The sedimentation of cell culture supernatant-de- density reported for immature HIV-virions and recombi-
nant Pr55gag-based VLPs. In all anti-p24(CA)-reactiverived particulate antigens was followed in 600-ml frac-
tions of 10 to 60% sucrose gradients using a commercial fractions, the presence of VLPs was demonstrated by
electron microscopical analysis after negative staining.sandwich assay (Abbott). Pr55gag was identified at a den-
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FIG. 4. Analysis of Sf9 cell lysates 3 days after coinfection with
recombinant AcNPVs expressing the Pr55gag polyprotein (m.o.i.  5)
and chimeric Env-TM proteins (m.o.i.  10). Sf9 cells were coinfected
with AcPr55 and Acgp120-TM (lanes 4), Acgp120-5TM (lanes 5),
Acgp120-20TM (lanes 6), and Acgp160 (lanes 7). Noninfected Sf9 insect
cells (lanes 1) or cells infected by AcWt (lanes 2) or coinfected with
AcWt and AcPr55 (lanes 3) were included as controls. Polypeptides
were separated by 10% SDS – PAGE and analyzed by immunoblotting
with (A) a p24(CA)-specific monoclonal antibody (mab 16/4/2) or (B) an
anti-gp120 monoclonal antibody (mab NEA 9305). Arrows on the right
indicate the position of the wild-type HIV Gag and Env proteins. Molecu-
lar weight marker positions are shown on the left in kilodaltons.
However, only fractions 12–14 were free of contaminat-
ing baculoviruses. Analysis of the collected fractions by
immunoblotting with both an anti-p24(CA) mab (16/4/2)
and a gp120-V3-specific monoclonal antibody (NEA 9305)
revealed coincidence of the Pr55gag precursor and the
Env proteins in sucrose fractions 10–14.
The amounts of particle-entrapped Env proteins were
calculated by Western immunoblotting. For that purpose,
VLPs were pelleted from pooled p24(CA) peak fractions
12–14 (1.15–1.19 g/cm3). Aliquots of resuspended VLP
preparations were separated by SDS–PAGE, immu-
FIG. 7. Sedimentation of chimeric Pr55gag/Env-TM VLPs from the cellnoblotted, and visualized with anti-Pr55gag mab 16/4/2
culture supernatant. (A) HIV Pr55gag- and chimeric Env-TM proteins
and a gp120/V3-specific monoclonal antibody (Figs. 7B were coexpressed in HighFive insect cells after coinfection with the
and 7C). Antibody 16/4/2 detected comparable amounts recombinant baculoviruses AcPr55 (m.o.i.  5) and Env-TM recombi-
nants (m.o.i.  10). For comparison insect cells were infected withof the unprocessed Pr55gag protein in all antigen prepara-
AcPr55 alone or coinfected with AcPr55 and wild-type AcNPVs or re-tions irrespectively from whether AcWt, Acgp120-TM,
combinant baculoviruses expressing Pr55gag and gp160. Supernatants
Acgp120-5TM, Acgp120-20TM, or Acgp160 was used in were harvested 3 days postinfection and preclarified at low speed.
the coinfection experiment (Fig. 7B). However, an approx- Particulate antigens were concentrated through a 30% sucrose cushion
and sedimented through a continuous sucrose gradient (10–60%).imately 50% decreased particle release was consistently
Twenty gradient fractions were collected and assayed for Pr55gag con-observed from all coinfected insect cells, when com-
tent by a commercial p24 capture assay (Abbott). Antigenic peaks con-pared to cells infected with AcPr55 alone (Fig. 7A). An
taining enriched VLPs were observed at a density of about 1.14–1.19
examination of these VLP preparations with a gp120/V3- g/cm3 (fractions 11–14). The indicated sucrose density profile (crosses,
specific monoclonal antibody (NEA 9305) revealed al- right ordinate) represent the mean values of all measured gradients;
standard deviations were always less than 2% of the mean. (B–D)most identical quantities of the chimeric glycoproteins
Western blots after electrophoresis of combined anti-p24(CA) reactivegp120-TM, gp120-5TM, and gp120-20TM, whereas only
sucrose gradient peak fractions (fractions 12–14) from supernatants
small amounts of the wild-type Env proteins were associ- of cells coinfected with AcPr55 and Acgp120-TM (lane 4), or Acgp120-
ated with these combined p24(CA)-positive sucrose frac- 5TM (lane 5), or Acgp120-20TM (lane 6), or Acgp160 (lane 7). Corre-
sponding sucrose fractions of separated supernatants of noninfectedtions (Fig. 7C, lane 7). Supernatants harvested from unin-
insect cells (lane 1) or cells coinfected with AcWt and Acgp120-TMfected cells or obtained from cells that were coinfected
(lane 2) or AcPr55 (lane 3) served as controls. Polypeptides of the
with AcWt and Acgp120-TM did not contain any of the combined p24(CA) sucrose gradient peak fractions were pelleted either
HIV antigens. (B, C) by acetone precipitation or (D, E) by immunoprecipitation using
a CD4-IgG chimeric antibody (CD4-2D-H23). Aliquots were analyzedTo further demonstrate that wild-type Env proteins and
by 10% SDS–PAGE and subsequent immunoblotting using specificthe derivatives of gp120 were not only copurified with
mabs recognizing (B, D) the p24(CA) protein (mab 16/4/2) and (C, E)the VLPs, coimmunoprecipitates of VLPs from sucrose
the gp120 V3-domain (mab NEA 9305). Arrows at the right indicate the
gradient peak fractions 12–14 were analyzed by SDS – position of the wild-type HIV Gag-and Env proteins. The positions of
PAGE and immunoblotting (Figs. 7D and 7E). The CD4- the molecular weight markers are indicated on the left (in kilodaltons).
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et al., 1990). To investigate the oligomeric structure ofIgG chimeric antibody precipitated the VLPs associated
particle-entrapped chimeric Env-TM proteins, sucrosewith gp120-TM, gp120-5TM, gp120-20TM, and gp160 as
gradient sedimented VLP preparations were treated withshown by the positive reaction of the anti-p24(CA) mab
the noncleavable, membrane-impermeable cross-linking(16/4/2) and the gp120/V3-specific antibody in the immu-
agent bis(sulfosuccinimidyl)suberate (BS3). After quench-noblot analysis. Even small quantities of VLP-entrapped
ing the cross-linking reaction, the VLPs were solubilizedwild-type Env proteins were sufficient for the precipitation
in presence of reducing agents, separated by low per-of hybrid Pr55/gp160 VLPs, as evidenced from the differ-
centage SDS–PAGE, and detected by immunoblottingences in the signal intensity obtained for Pr55gag with
with a gp120/V3-specific monoclonal antibody. Non-mab 16/4/2 and for HIV-Env achieved with a gp120/V3-
cross-linked anti-gp120 reactive bands of approximatelyspecific monoclonal antibody (Figs. 7D and 7E, lanes 7).
137, 135, and 132 kDa represent the monomeric forms
The CD4-IgG chimera did not precipitate Pr55gag particles
of the chimeric gp120-TM, gp120-5TM, and gp120-20TM
without coexpressed HIV-1 Env sequences (Figs. 7D and Env proteins (Fig. 9A, lanes 1–3). The molecular weights
7E, lanes 3). of the anti-gp120 reactive bands have been estimated
The presence of HIV-Env and chimeric Env-TM poly- with reference to particle-entrapped gp160, gp120 (Fig.
peptides on the surface of VLPs was further confirmed 9A, lane 4), and purified rgp160 Env protein species (lane
by immunoelectron microscopy. The CD4-IgG chimeric 5) and were consistent with other commercial high mo-
antibody specifically bound to sucrose gradient-purified lecular weight standards (Sigma, Deisenhofen, Ger-
Pr55gag/gp160 (Fig. 8B) as well as Pr55gag/gp120-TM many). By using low concentrations of BS3 (0.3 mM) an
VLPs (Figs. 8C and 8D) as detected by an anti-mouse additional dominant anti-gp120 reactive protein band ap-
IgG gold conjugate. Negative controls included Pr55gag/ peared in samples of Pr55gag/Env VLPs presenting the
gp120-TM VLP preparations incubated with an irrelevant different Env-TM derivatives, apparently migrating as
antibody recognizing the external portion of the EBV ma- 240- to 250-kDa proteins (Fig. 9B, lanes 1–3). In contrast
jor glycoprotein gp220/350 (mab 64D7) as well as VLPs only minute quantities of cross-linked products were de-
purified from the supernatants of HighFive cell cultures tected in Pr55gag/gp160 VLP probes (Fig. 9B, lane 4).
infected with AcPr55 and incubated with the CD4-IgG Thus, these results indicate a close and, in comparison
to the wild-type Env proteins, enhanced association ofconstruct. In these preparations, no gold-labeling of VLPs
particle-entrapped Env-TM polypeptides.was observed (Fig. 8A).
Analysis of Pr55gag/Env-TM samples, which wereTo further estimate the amounts of wild-type Env pro-
treated with higher concentrations of BS3 (1.5 mM), re-teins or gp120 derivatives incorporated into the mem-
vealed the appearance of a third anti-gp120 reactivebrane of recombinant VLPs, antigens harvested from su-
band migrating at a high molecular weight and possiblycrose gradient fractions 12–14 were quantified using a
representing trimers or more probably tetramers of thecommercial p24(CA) sandwich assay (Abbott). Identical
chimeric Env proteins (Fig. 9C, lanes 1–3). A band withamounts of VLPs (20 mg) were separated by SDS – PAGE
a similar molecular weight was also visualized in cross-together with twofold serial dilutions of purified rgp120
linked samples of Pr55gag/gp160 VLPs (Fig. 9C, lane 4).(0.2 to 3.2 mg) as a calibration curve. The recombinant
No further anti-gp120 reactive bands were detected evenproteins were readily detected by an anti-gp120/V3
in the presence of higher concentrations of the cross-monoclonal antibody. Comparison of the signal intensi-
linking reagent (3 mM, 6 mM) (data not shown). Thus, atties detected in the VLP preparations with those of the
high concentrations of BS3 the cross-linked wild-type Envcalibration curve suggested an estimated proportion of
proteins almost quantitatively consisted of a high orderabout 0.2 mg wild-type Env proteins incorporated into 20
oligomer, presumably a tetramer, whereas, as a conse-
mg of Pr55gag/gp160 VLPs. However, as compared to
quence of cross-linking, the gp120 derivatives were de-
wild-type HIV Env polypeptides significantly increased tected in two higher molecular bands as proposed di-
concentrations of hybrid Env-TM proteins, ranging from mers and to a minor extent as higher-order oligomeric
0.8 to 1.2 mg were quantified in 20 mg of Pr55gag/gp120- species.
TM preparations. Similar results were obtained for To investigate whether the high molecular weight anti-
Pr55gag/gp120-5TM and Pr55gag/gp120-20TM VLPs (data gp120 reactive bands represent pure oligomers of the
not shown). Env-TM derivatives, we probed parallel blots with mono-
clonal anti-p24(CA) reactive monoclonal antibodies (mab
Oligomeric organization of particle-entrapped Env-TM 16/4/2). The observed anti-gp120 reactive bands did not
glycoproteins react with p24(CA)-specific antibodies, indicating that
these specific bands did not contain Pr55gag polyproteins
Previous studies have indicated that the HIV gp160 crosslinked to the Env-TM chimeras (data not shown).
precursor as well as the gp41 transmembrane protein
DISCUSSIONare capable of forming stable oligomers, whereas the
We and others have previously shown, that the expres-isolated gp120 subunit readily dissociates into mono-
mers (Schawaller et al., 1989; Pinter et al., 1989; Earl sion of the HIV Pr55gag precursor protein by recombinant
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FIG. 8. Immunoelectron microscopy of concentrated particles. Sucrose gradient sedimented (A) Pr55gag, (B) Pr55gag/gp160 and (C) Pr55gag/gp120-
TM VLP preparations (fractions 11–14, Fig. 7) were adsorbed to grids and incubated with anti-gp120 mab 133/237. Bound mab 133/237 was detected
with an anti-mouse IgG gold conjugate and analyzed by electron microscopy. Env proteins were specifically detected on VLPs secreted by Sf9
insect cells coinfected with Pr55gag- and Env-recombinant baculoviruses. Clusters of immunogold-labeled Env proteins are indicated by black arrows.
(D) A representative immunogold-labeled Pr55gag/gp120-TM VLP with distinct regions of clustered gp120-TM proteins. No specific labeling of particles
was seen in negative controls.
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induced by the HIV-1 transmembrane protein gp41
(Young, 1988; Ruegg et al., 1989; Robinson, Jr. et al., 1990;
Denner et al., 1994); (ii) a significantly, by a factor of 5–10,
increased incorporation of oligomeric gp120 chimeras
on the surface of immunostimulative Pr55gag lipoprotein
particles; and (iii) the absence of the diagnostically rele-
vant gp41, which will allow a serological discrimination of
vaccinees and HIV-infected people in future vaccination
studies.
Biochemical and FACScan analysis revealed that all
variants of the chimeric Env-TM protein were synthe-
sized, transported to the cell membrane, and incorpo-
FIG. 9. Crosslinking of Env-TM derivatives on the surface of VLPs. rated on the outer surface of insect cells at levels compa-Western blot with anti-gp120 monoclonal antibody of a 5% SDS–poly-
rable to that of wild-type HIV Env-proteins. These resultsacrylamide gel. HighFive insect cells were coinfected with baculovi-
extend previous observations that the transmembraneruses expressing the Pr55gag polyprotein and gp120-TM (lane 1), gp120-
5TM (lane 2), gp120-20TM (lane 3), or gp160 (lane 4) (m.o.i.  5 for and cytoplasmic domain of gp41 is dispensable for an
each recombinant AcNPV). At Day 3 p.i. VLPs were pelleted from the efficient trafficking and glycoprotein incorporation into
supernatant by spinning the cell-free supernatant through a 30% su- the membranes of various mammalian cell-lines (Ga-crose cushion. The resulting pellet was resuspended in PBS, loaded
buzda et al., 1992; Wilk et al., 1992, 1996; Salzwedel eton a 10– 60% sucrose gradient in PBS, and centrifuged at 100,000 g
al., 1993). However, the simultaneous expression of thefor 16 hr at 47. The antigens sedimenting at 1.15–1.19 g/cm3 were
collected and pelleted at 100,000 g for 2.5 hr at 47. The resuspended Pr55gag polyprotein caused a significantly reduced cell
VLP preparations were then incubated with the crosslinking reagent surface exposure of wild-type Env proteins, when com-
BS3 at concentrations of (B) 0.3 or (C) 1.5 mM for 30 min at room pared to that of the chimeric Env-TM proteins. Moreovertemperature. The reaction was stopped by quenching with 50 mM
the exchange of gp41 by the EBV gp220/350-derivedTris, pH 7.5. (A) Non-cross-linked VLP preparations (lanes 1–4) and
transmembrane domain even resulted in a 5- to 10-foldrecombinant gp160 proteins (lane 5) were used as controls. Probes
were solubilized, subjected to SDS–PAGE and Western blot analysis increased amount of particle-associated glycoproteins
using an anti-gp120/V3 antibody, and then analyzed by enhanced compared to wild-type Env proteins.
chemoluminescence (ECL) (Amersham). Arrows indicate the anti- The mechanisms and signals involved in the selectivegp120-reactive bands interpreted as monomers, dimers, and tetramers.
incorporation of cellular and heterologous proteins into
HIV-virions and Pr55gag VLPs are not completely under-
stood so far and appear to be cell-type-specific. For thebaculoviruses results in the formation of large quantities
of noninfectious particulate structures that retain many HIV Env proteins, several data demonstrated the require-
ment of an interaction between distinct regions withinof the physical properties of immature HIV virions
(Gheysen et al., 1989; Overton et al., 1989; Royer et al., the extremely long cytoplasmic domain of the HIV trans-
membrane protein gp41 and the p17 matrix domain of1991; Wagner et al., 1992). These virus-like particles
(VLP) can be easily produced in a substantially pure form the Pr55gag precursor (Yu et al., 1992,, 1993; Dorfman et
al., 1994; Freed et al., 1995; Freed and Martin, 1995),using conventional purification techniques and have
been demonstrated to be very potent stimuli of the im- resulting in a specific incorporation of Env proteins into
HIV virions that is limited to approximately 72 Env projec-mune system. Accordingly we and others have previously
demonstrated the capability of presenting selected HIV- tions (Gelderblom et al., 1989). Alterations in the cyto-
plasmic moiety of the SIV and HIV-2 transmembrane do-derived immunogenic determinants by inserting these
epitopes at various positions within the particle forming main significantly increased the level of Env proteins on
virions (Mulligan et al., 1992; Zingler and Littman, 1993;Pr55gag polyprotein (Luo et al., 1992; Griffiths et al., 1993;
Wagner et al., 1994; Brand et al., 1995). LaBranche et al., 1995) and VLPs (Yamshchikov et al.,
1995), whereas various deletions in the C-terminal regionAiming at the development of a more complex VLP-
based candidate vaccine we constructed antigenetically of the cytoplasmic region of HIV-1 gp41 were shown to
reduce the incorporation of Env proteins into virus parti-extended Pr55gag virus-like particles presenting high
quantities of oligomeric HIV-1 gp120 proteins at the outer cles (Dubay et al., 1992; Yu et al., 1993). Regarding the
increased incorporation of Env-TM into VLPs one couldparticle surface. Therefore, various chimeric HIV-1 Env
proteins were established in which the complete trans- assume that these chimeric proteins, lacking a long cyto-
plasmic domain such as that of wild-type gp41, are capa-membrane protein gp41 was replaced by a heterologous
transmembrane and cytoplasmic moiety of the EBV gly- ble of being incorporated into VLPs without the need of
a specific interaction with the Pr55gag polyprotein. Thiscoprotein gp220/350. As compared to the wild-type HIV
gp160 protein the particle-associated chimeric gp120- suggestion is supported by a very recent report of Wilk
and coworkers, demonstrating that recombinant gp160TM derivatives possess some intrinsic advantages for
vaccine purposes: (i) an exclusion of immunosuppressive harboring the membrane spanning region and long cyto-
plasmic domain from the cellular glycoprotein CD22 wereeffects and adverse immune reactions suggested to be
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excluded from particle incorporation, probably because a tetrameric rather than a trimeric molecule. Third, the
chimeric Env-TM and wild-type HIV-Env proteins formof steric hindrances. However, the deletion of the spa-
cious foreign cytoplasmic domain restored the particle higher-order oligomers with a similar molecular mass,
and gp160, gp120, as well as gp41 are suggested toincorporation of the chimeric Env protein, approximately
to wild-type level (Wilk et al., 1996). Glycoprotein incorpo- have tetrameric structures (Pinter et al., 1989; Schawaller
et al., 1989; Earl et al., 1990; Owens and Compans, 1990;ration in Pr55gag VLPs has been also observed with mu-
tant glycoproteins hooked to the membrane by a glyco- Weiss et al., 1990), as do the glycoprotein precursors of
HIV-2 and SIV (Rey et al., 1989; Chakrabarti et al., 1990;syl-phosphatidylinositol (GPI) attachment signal (Salz-
wedel et al., 1993). Consistent with our observations, the Rey et al., 1990). However, as compared to the wild-type
Env proteins, the dimeric form of the Env-TM polyproteinsexchange of the transmembrane domain of gp41 by a
GPI anchor resulted in a drastically increased amount of appears to be more stable. Thus, given all of the con-
siderations, we suggest that the Env-TM proteins formparticle entrapped glycoproteins.
The incorporation of chimeric Env-TM proteins into dimers that assemble into tetramers composed of two
dimers. For wild-type HIV Env proteins, the relatively con-released particles was clearly indicated by sucrose gra-
dient fractionation studies of concentrated Pr55gag/Env served gp41 ectodomain is responsible for oligomeriza-
tion of gp160, whereas the cytoplasmic and transmem-particles and subsequent immunoprecipitation of sedi-
mented pseudovirions with gp120-specific antibodies. brane domains are not essential (Earl et al., 1990; Earl
and Moss, 1993; Hallenberger et al., 1993; PoumbouriosThe chimeric Env-TM proteins, as well as wild-type
gp160, have been detected mainly in those sucrose frac- et al., 1995). Regarding that chimeric Env-TM polypro-
teins lacking the complete gp41 protein have beentions that also contained VLPs. Furthermore, Pr55gag
VLPs presenting chimeric or wild-type Env proteins but shown to readily oligomerize, our results extend previous
studies, suggesting that HIV-1 Env protein oligomeriza-not Env negative Pr55gag VLPs were specifically coprecip-
itated by Env-specific antibodies, indicating a close asso- tion is mediated by multiple domains within gp41 and
gp120 (Poumbourios et al., 1995). Further studies areciation of the Env proteins with the particulate carrier
component. Particle-associated Env protein consisted of needed to elucidate whether domains within the EBV-
transmembrane or cytoplasmic region are involved in thealmost equal quantities of unprocessed and processed
aggregation of the chimeric Env-TM proteins. However,forms of the gp160 precursor protein or uncleaved Env-
it is likely that the overall conformation of the extracellularTM chimeras. These observations support previous re-
gp120 domain of the Env-TM proteins may not be signifi-ports indicating that the targeting of HIV-Env proteins to
cantly affected by the addition of the heterologous EBV-the surface of VLPs does not essentially require endopro-
derived transmembrane region, although the oligomericteolytic cleavage (Rovinski et al., 1995; Tobin et al., 1996).
state of the Env proteins might be analyzed more pre-Furthermore, immunoelectron microscopical analysis
cisely in future studies by using antibodies specificallywas performed to determine the distribution of the chime-
recognizing Env oligomers.ric Env-TM proteins on the surface of the Pr55gag VLPs,
Aiming at the development of more complex HIV candi-as it currently provides the most convincing means to
date vaccines we have suggested a novel strategy todemonstrate the specific association and location of Env
incorporate high quantities of chimeric gp120 oligomersproteins on recombinant Pr55gag particles (Gelderblom et
at the outer surface of Pr55gag virus-like particles thatal., 1987; Gonda, 1994). The VLP surface labeling unam-
have been previously demonstrated to be highly immuno-biguously demonstrated the presence of chimeric Env-
genic in absence of adjuvant (Wagner et al., 1996). TheTM proteins on the exterior of sucrose gradient-purified
HIV Pr55gag polyprotein and oligomeric envelope proteinsparticles, confirming a close association of the Env chi-
represent major targets for the cell-mediated (Gag, Env)meras with the VLPs.
(Nixon et al., 1988; Koup et al., 1991; Buseyne et al.,A common feature for the Env glycoproteins of HIV
1993; Harrer et al., 1996) and cross-neutralizing humoraland other enveloped viruses is their oligomeric structure.
immune response (oligomeric Env-proteins) (Steimer etOur cross-linking analysis indicate that the chimeric Env-
al., 1991; Sattentau and Moore, 1995, Fouts et al., 1997).TM proteins are organized as dimers and higher order
Work in progress demonstrates that these nonreplicatingoligomers on the particle surface. Due to the large size
Pr55gag/Env pseudovirions are capable of inducing bothof this complex, it is difficult to determine its degree of
humoral and CD8/ CTL responses in rodents and mon-oligomerization with absolute certainty, as well-charac-
keys (Deml et al., 1997; Teeuwsen et al., manuscript interized molecular weight markers are not available. How-
preparation). Therefore, nonreplicating Pr55gag/Env pseu-ever, several considerations led us to conclude that the
dovirions provide a promising candidate immunogen forhigher order form is tetrameric. First, consistent recovery
the development of a safe and efficacious particle-basedof a predominant dimer band suggests that these form
AIDS vaccine.the ‘‘building block’’ of any higher order structure. Thus,
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